您的位置:山东大学 -> 科技期刊社 -> 《山东大学学报(医学版)》

山东大学学报 (医学版) ›› 2022, Vol. 60 ›› Issue (7): 20-25.doi: 10.6040/j.issn.1671-7554.0.2022.0407

• 子宫腺肌病研究专题 • 上一篇    下一篇

子宫腺肌病的药物治疗进展

彭超,周应芳   

  1. 北京大学第一医院妇产科, 北京 100034
  • 发布日期:2022-07-27
  • 通讯作者: 周应芳. E-mail:zhouyf8853@163.com
  • 基金资助:
    国家重点研发计划(2017YFC1001200)

Progress on the medical treatment of adenomyosis

PENG Chao, ZHOU Yingfang   

  1. Department of Obstetrics and Gynecology, Peking University First Hospital, Beijing 100034, China
  • Published:2022-07-27

摘要: 缓解疼痛,减少出血和促进生育是子宫腺肌病的主要治疗目标。腺肌病药物治疗选择与子宫内膜异位症类似,有非甾体类抗炎药、促性腺激素释放激素类似物(GnRH-a)、复方口服避孕药、孕激素类药物以及中医中药等五大类。子宫腺肌病是一种慢性疾病,需要长期管理。

关键词: 子宫腺肌病, 药物治疗, 长期管理

Abstract: Pain relief, bleeding reduction and fertility promotion are the main therapeutic goals of adenomyosis. The medical drugs for the treatment of adenomyosis are similar to those of endometriosis, including non-steroidal anti-inflammatory drugs, gonadotropin releasing hormone analogues(GnRH-a), compound oral contraceptives, progesterone drugs and traditional Chinese medicine. Adenomyosis is a chronic disease that requires long-term management.

Key words: Adenomyosis, Medical treatment, Long-term management

中图分类号: 

  • R711.74
[1] 中国医师协会妇产科医师分会子宫内膜异位症专业委员会. 子宫腺肌病诊治中国专家共识[J]. 中华妇产科杂志, 2020, 55(6): 376-383.
[2] 中国医师协会妇产科医师分会, 中华医学会妇产科学分会子宫内膜异位症协作组. 子宫内膜异位症诊治指南(第三版)[J]. 中华妇产科杂志, 2021, 56(12): 812-824.
[3] 郎景和. 子宫腺肌症的迷惑与解惑[J]. 中华妇产科杂志, 2020, 55(11): 737-739.
[4] 彭超, 周应芳. 子宫内膜异位症的药物治疗[J]. 山东大学学报(医学版), 2019, 57(6): 46-50. PENG Chao, ZHOU Yingfang. Medical treatment of endometriosis: an update [J]. Journal of Shandong University(Health Sciences), 2019, 57(6): 46-50.
[5] Taylor HS, Kotlyar AM, Flores VA. Endometriosis is a chronic systemic disease: clinical challenges and novelinnovations [J]. Lancet, 2021, 397(10276): 839-852.
[6] 中华医学会妇产科学分会子宫内膜异位症协作组. 子宫内膜异位症长期管理中国专家共识[J]. 中华妇产科杂志, 2018, 53(12): 836-841.
[7] Vannuccini S, Luisi S, Tosti C, et al. Role of medical therapy in the management of uterine adenomyosis [J]. Fertil Steril, 2018, 109(3): 398-405.
[8] 彭超, 周应芳. 子宫腺肌病药物治疗选择及长期管理[J]. 中国实用妇科与产科杂志, 2019, 35(5): 516-519. PENG Chao, ZHOU Yingfang. Drug choice in medical therapy and long-term management for patients with adenomuosis of the uterus [J]. Chinese Journal of Practical Gynecology and Obstetrics, 2019, 35(5): 516-519.
[9] No authors listed. ACOG Committee Opinion No. 760 Summary: dysmenorrhea and endometriosis in the adolescent [J]. Obstet Gynecol, 2018, 132(6): 1517-1518.
[10] 彭超, 周应芳. 药物治疗在子宫内膜异位症长期管理中的应用和选择[J]. 中国实用妇科与产科杂志, 2021, 37(3): 303-308. PENG Chao, ZHOU Yingfang. Application and selection of medical treatment in the long-term management of endometriosis [J]. Chinese Journal of Practical Gynecology and Obstetrics, 2021, 37(3): 303-308.
[11] Brown J, Crawford TJ, Allen C, et al. Nonsteroidal anti-inflammatory drugs for pain in women with endometriosis [J]. Cochrane Database Syst Rev, 2017, 1(1): CD004753.
[12] Oladosu FA, Tu FF, Hellman KM. Nonsteroidal anti-inflammatory drug resistance in dysmenorrhea: epidemiology, causes, and treatment [J]. Am J Obstet Gynecol,2018, 218(4): 390-400.
[13] ETIC Endometriosis Treatment Italian Club. When more is not better: 10'don'ts' in endometriosis management. An ETIC* position statement [J]. Hum Reprod Open, 2019, 2019(3): hoz009.
[14] 石一复, 张信美, 黄秀峰, 等. 子宫腺肌症[M]. 北京: 人民卫生出版社, 2018: 129-142.
[15] Chapron C, Marcellin L, Borghese B, et al. Rethinking mechanisms, diagnosis and management of endometriosis [J]. Nat Rev Endocrinol, 2019, 15(11): 666-682.
[16] 彭超, 周应芳. 子宫腺肌病的药物治疗新探索[J]. 中国计划生育和妇产科, 2019, 11(4): 18-20.
[17] Matsushima T, Akira S, Fukami T, et al. Efficacy of hormonal therapies for decreasing uterine volume in patients with adenomyosis [J]. Gynecol Minim Invasive Ther, 2018, 7(3): 119-123.
[18] 周应芳. 子宫腺肌病药物治疗原则及注意事项[J]. 中国实用妇科与产科杂志, 2017, 34(2): 157-160. ZHOU Yingfang. Principles and precautions of medical treatment for adenomyosis of the uterus [J]. Chinese Journal of Practical Gynecology and Obstetrics, 2017, 34(2): 157-160.
[19] Taylor HS, Giudice LC, Lessey BA, et al. Treatment of endometriosis-associated pain with Elagolix, an oral GnRH antagonist [J]. N Engl J Med, 2017, 377(1): 28-40.
[20] Surrey E, Taylor HS, Giudice L, et al. Long-term outcomes of Elagolix in women with endometriosis: results from two extension studies [J]. Obstet Gynecol, 2018, 132(1): 147-160.
[21] Barra F, Grandi G, Tantari M, et al. A comprehensive review of hormonal and biological therapies for endometriosis: latest developments [J]. Expert Opin Biol Ther, 2019, 19(4): 343-360.
[22] Perricos A, Wenzl R. Efficacy of elagolix in the treatment of endometriosis [J]. Expert Opin Pharmacother, 2017, 18(13): 1391-1397.
[23] Vercellini P, Viganò P, Barbara G, et al. Elagolix for endometriosis: all that glitters is not gold [J]. Hum Reprod, 2019, 34(2): 193-199.
[24] Barra F, Vitale SG, Seca M, et al. The potential role of elagolix for treating uterine bleeding associated to uterine myomas [J]. Expert Opinion on Pharmacotherapy, 2020, 21(12): 1419-1430.
[25] Al-Hendy A, Bradley L, Owens CD, et al. Predictors of response for elagolix with add-back therapy in women with heavy menstrual bleeding associated with uterine fibroids [J]. Am J Obstet Gynecol, 2021, 224(1): 72.
[26] Muneyyirci-Delale O, Archer DF, Owens CD, et al. Efficacy and safety of elagolix with add-back therapy in women with uterine fibroids and coexisting adenomyosis [J]. F S Rep, 2021, 2(3): 338-346.
[27] Donnez J, Stratopoulou CA, Dolmans MM. Uterine adenomyosis: from disease pathogenesis to a new medical approach using GnRH antagonists [J]. Int J Environ Res Public Health, 2021, 18(19): 9941.
[28] Donnez O, Donnez J. Gonadotropin-releasing hormone antagonist(linzagolix): a new therapy for uterine adenomyosis [J]. Fertil Steril, 2020, 114(3): 640-645.
[29] Donnez J, Donnez O, Tourniaire J, et al. Uterine adenomyosis treated by Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist: a pilot study with a New ‘Hit Hard First and then Maintain’ regimen of administration [J]. J Clin Med, 2021, 10(24): 5794.
[30] 复方口服避孕药临床应用中国专家共识专家组. 复方口服避孕药临床应用中国专家共识[J]. 中华妇产科杂志, 2015, 50(2): 81-91.
[31] 周应芳, 彭超, 冷金花. 要重视子宫内膜异位症的一级和二级预防[J]. 中华妇产科杂志, 2020, 55(9): 624-626.
[32] Shaaban OM, Ali MK, Sabra AM, et al. Levonorgestrel-releasing intrauterine system versus a low-dose combined oral contraceptive for treatment of adenomyotic uteri: a randomized clinical trial [J]. Contraception, 2015, 92(4): 301-307.
[33] Wu J, Huang Y, Chen L, et al. Treatment of adenomyosis with subcutaneous etonogestrel implants: a clinical observational study in 17 patients [J]. Med Sci Monit, 2018, 24: 6085-6092. doi: 10.12659/MSM.908979.
[34] Murji A, Biberoglu K, Leng J, et al. Use of dienogest in endometriosis: a narrative literature review and expert commentary [J]. Curr Med Res Opin, 2020, 36(5): 895-907.
[35] Caruso S, Iraci M, Cianci S, et al. Effects of long-term treatment with Dienogest on the quality of life and sexual function of women affected by endometriosis-associated pelvic pain [J]. J Pain Res, 2019, 12: 2371-2378. doi:10.2147/JPR.S207599.
[36] Lang J, Yu Q, Zhang S, et al. Dienogest for treatment of endometriosis in Chinese women: a placebo-controlled, randomized, double-blind phase 3 study [J]. J Womens Health(Larchmt), 2018, 27(2): 148-155.
[37] Osuga Y, Fujimoto-Okabe H, Hagino A. Evaluation of the efficacy and safety of dienogest in the treatment of painful symptoms in patients with adenomyosis: a randomized, double-blind, multicenter, placebo-controlled study [J]. Fertil Steril, 2017, 108(4): 673-678.
[38] 徐冰, 陈文勤. 子宫内膜异位症治疗药物地诺孕素的研究进展[J]. 中华妇产科杂志, 2016, 51(3): 222-224.
[39] 徐冰, 李华军, 贾婉璐, 等. 地诺孕素用于难治性子宫内膜异位症疼痛的临床研究[J]. 中华妇产科杂志, 2021, 56(3): 178-184.
[40] Takeuchi A, Koga K, Miyashita M, et al. Dienogest reduces proliferation, NGF expression and nerve fiber density in human adenomyosis [J]. Eur J Obstet Gynecol Reprod Biol, 2016, 207: 157-161. doi: 10.1016/j.ejogrb.2016.10.053.
[41] Prathoomthong S, Tingthanatikul Y, Lertvikool S, et al. The effects of dienogest on macrophage and natural killer cells in adenomyosis: a randomized controlled study [J]. Int J Fertil Steril, 2018, 11(4): 279-286.
[42] Ji M, Yuan M, Jiao X, et al. A cohort study of the efficacy of the dienogest and the gonadotropin-releasinghormone agonist in women with adenomyosis and dysmenorrhea [J]. Gynecol Endocrinol, 2022, 38(2): 164-169.
[43] Matsushima T, Akira S, Yoneyama K, et al. Recurrence of uterine adenomyosis after administration of gonadotropin-releasing hormone agonist and the efficacy of dienogest [J]. Gynecol Endocrinol, 2020, 36(6): 521-524.
[44] Neriishi K, Hirata T, Fukuda S, et al. Long-term dienogest administration in patients with symptomatic adenomyosis [J]. J Obstet Gynaecol Res, 2018, 44(8): 1439-1444.
[45] Nirgianakis K, Vaineau C, Agliati L, et al. Risk factors for non-response and discontinuation of dienogest in endometriosispatients: a cohort study [J]. Acta Obstet Gynecol Scand, 2021, 100(1): 30-40.
[46] Matsubara S, Kawaguchi R, Akinishi M, et al. Subtype I(intrinsic)adenomyosis is an independent risk factor fordienogest-related serious unpredictable bleeding in patients with symptomatic adenomyosis [J]. Sci Rep, 2019, 9(1): 17654.
[47] Osuga Y, Watanabe M, Hagino A. Long-term use of dienogest in the treatment of painful symptoms in adenomyosis [J]. J Obstet GynaecolRes, 2017, 43(9): 1441-1448.
[48] 黄艳, 彭超, 周应芳. 地诺孕素治疗子宫腺肌病的研究进展[J]. 中华妇产科杂志, 2021, 56(12): 876-880.
[49] Bahamondes L, Valeria Bahamondes M, Hulman LP. Non-contraceptive benefits of hormonal and intrauterine reversible contraceptive methods [J]. Hum Reprod Update, 2015, 21(5): 640-651.
[50] 程利南, 狄文, 丁岩, 等. 女性避孕方法临床应用的中国专家共识[J]. 中华妇产科杂志, 2018, 53(7): 1-15.
[51] 郎景和, 冷金花, 邓姗, 等. 左炔诺孕酮宫内缓释系统临床应用的中国专家共识[J]. 中华妇产科杂志, 2019, 54(12): 815-825.
[52] Benetti-Pinto CL, de Mira TAA, Yela DA, et al. Pharmacological treatment for symptomatic adenomyosis: a systematic review [J]. Rev Bras Ginecol Obstet, 2019, 41(9): 564-574.
[53] 李雷, 冷金花, 戴毅, 等. LNG-IUS治疗子宫腺肌病相关重度痛经的前瞻性研究[J]. 中华妇产科杂志, 2016, 51(5): 345-351.
[54] 邓婷, 周应芳. 左炔诺孕酮宫内缓释系统下移和脱落的危险因素及防治措施[J]. 中华妇产科杂志, 2019, 54(12): 780-783.
[55] 邓婷, 彭超, 黄艳, 等. 影响宫腔镜下放置左炔诺孕酮宫内节育系统脱落的多因素分析[J]. 中国微创外科杂志, 2020, 20(8): 673-677. DENG Ting, PENG Chao, HUANG Yan, et al. Multivariate analysis of influence factors of expulsion of levonorgestrel-releasing intrauterine system inserted by hysteroscopy [J]. Chinese Journal of Minimally Invasive Surgery, 2020, 20(8): 673-677.
[56] Che X, Wang J, He J, et al. New application of mifepristone in the treatment of adenomyosis dysmenorrhea [J]. Int J Med Sci, 2020, 17(2): 224-233.
[57] 周应芳.子宫肌瘤药物治疗之评价[J]. 实用妇产科杂志, 2016, 32(3): 180-182.
[58] Cope AG, Ainsworth AJ, Stewart EA. Current and future medical therapies for adenomyosis [J]. Semin Reprod Med, 2020, 38(2-03): 151-156.
[59] Baboo Kalianee Devi, 陈正云, 张信美. 子宫腺肌病患者药物治疗进展[J]. 浙江大学学报(医学版), 2019, 48(2): 142-147. Baboo Kalianee Devi, CHEN Zhengyun, ZHANG Xinmei. Progress on medical treatment in the management of adenomyosis [J]. Journal of Zhejiang University(Medical Sciences), 2019, 48(2): 142-147.
[60] 王国云, 王凯, 袁明, 等. 子宫内膜异位症立体化管理体系(山东方案)[J]. 山东大学学报(医学版), 2021, 59(10): 1-16. WANG Guoyun, WANG Kai, YUAN Ming, et al. Multidimensional management system for endometriosis(The Program for Shandong Provence)[J]. Journal of Shandong University(Health Sciences), 2021, 59(10): 1-16.
[1] 王国云,潘臧钰. 子宫腺肌病动物模型研究进展[J]. 山东大学学报 (医学版), 2022, 60(7): 48-55.
[2] 颜磊,陈子江. 子宫腺肌病合并不孕的治疗[J]. 山东大学学报 (医学版), 2022, 60(7): 43-47.
[3] 陶国伟,王芳,董向毅,徐亚瑄,赵琳丽,胡蓓蓓. 子宫腺肌病的超声与MRI诊断及进展[J]. 山东大学学报 (医学版), 2022, 60(7): 56-65.
[4] 艾星子·艾里,郭铮宇,张晓霏. 子宫腺肌病高强度聚焦超声消融治疗研究进展[J]. 山东大学学报 (医学版), 2022, 60(7): 36-42.
[5] 易晓芳,黄季华. 子宫腺肌病的患者教育及全程管理[J]. 山东大学学报 (医学版), 2022, 60(7): 32-35.
[6] 张信美,徐萍. 子宫腺肌病的手术治疗策略[J]. 山东大学学报 (医学版), 2022, 60(7): 26-31.
[7] 冷金花, 史精华. 子宫腺肌病的临床表现[J]. 山东大学学报 (医学版), 2022, 60(7): 1-5.
[8] 郭孙伟,刘惜时. 子宫腺肌病发病机制和病理生理研究进展[J]. 山东大学学报 (医学版), 2022, 60(7): 6-19.
[9] 徐歌,李青,张灿灿,田永杰. 子宫腺肌病组织及原代细胞中PARP-1、HIF-1α的表达及临床意义[J]. 山东大学学报 (医学版), 2022, 60(4): 55-61.
[10] 耿晨,杨阳,赵月,刘浩冉,晁岚. 子宫腺肌病中差异基因筛选及Wilms tumor-1的表达[J]. 山东大学学报 (医学版), 2021, 59(4): 79-86.
[11] 杨贵霞,徐阳,马明明,宋然,朱鹏飞. 宫腹腔镜联合治疗Robert子宫合并子宫腺肌病1例[J]. 山东大学学报 (医学版), 2021, 59(1): 122-124.
[12] 王冰玉,杨阳,晁岚. TOLL样受体4在15例子宫腺肌病中的表达及作用[J]. 山东大学学报 (医学版), 2020, 58(6): 47-52.
[13] 彭超,周应芳. 子宫内膜异位症的药物治疗[J]. 山东大学学报 (医学版), 2019, 57(6): 46-50.
[14] 冷金花,史精华. 子宫内膜异位症长期管理策略[J]. 山东大学学报 (医学版), 2019, 57(6): 1-5.
[15] 林雪艳,李春艳,侯小满,田永杰. PARP-1及EMT标志物在子宫腺肌病在位及异位内膜中的表达[J]. 山东大学学报(医学版), 2017, 55(9): 36-40.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] 索东阳,申飞,郭皓,刘力畅,杨惠敏,杨向东. Tim-3在药物性急性肾损伤动物模型中的表达及作用机制[J]. 山东大学学报 (医学版), 2020, 1(7): 1 -6 .
[2] 马青源,蒲沛东,韩飞,王超,朱洲均,王维山,史晨辉. miR-27b-3p调控SMAD1对骨肉瘤细胞增殖、迁移和侵袭作用的影响[J]. 山东大学学报 (医学版), 2020, 1(7): 32 -37 .
[3] 徐玉香,刘煜东,张蓬,段瑞生. 101例脑小血管病患者脑微出血危险因素的回顾性分析[J]. 山东大学学报 (医学版), 2020, 1(7): 67 -71 .
[4] 丁祥云,于清梅,张文芳,庄园,郝晶. 胰岛素样生长因子II在84例多囊卵巢综合征患者颗粒细胞中的表达和促排卵结局的相关性[J]. 山东大学学报 (医学版), 2020, 1(7): 60 -66 .
[5] 郭志华,赵大庆,邢园,王薇,梁乐平,杨静,赵倩倩. Ⅰ期端端吻合术治疗重度颈段气管狭窄临床分析[J]. 山东大学学报 (医学版), 2020, 1(7): 72 -76 .
[6] 吕龙飞,李林,李树海,亓磊,鲁铭,程传乐,田辉. 腔镜下细针导管空肠造瘘在微创McKeown食管癌切除术中的应用[J]. 山东大学学报 (医学版), 2020, 1(7): 77 -81 .
[7] 张娟,张璐嘉,肖伟,李顺平. 住院医师规范化培训学员压力知觉与留职意愿及影响因素[J]. 山东大学学报 (医学版), 2020, 1(7): 108 -114 .
[8] 罗昕,何兵,聂清生,侯震波,董军,李玉花,曾祥芹,刘伟,孔德民,曹金凤. 磁共振扩散加权成像单指数模型与扩散峰度成像模型在61例肾透明细胞癌分级中的对比[J]. 山东大学学报 (医学版), 2020, 1(7): 89 -95 .
[9] 龙婷婷,谢明,周璐,朱俊德. Noggin蛋白对小鼠脑缺血再灌注损伤后学习和记忆能力与齿状回结构的影响[J]. 山东大学学报 (医学版), 2020, 1(7): 15 -23 .
[10] 李宁,李娟,谢艳,李培龙,王允山,杜鲁涛,王传新. 长链非编码RNA AL109955.1在80例结直肠癌组织中的表达及对细胞增殖与迁移侵袭的影响[J]. 山东大学学报 (医学版), 2020, 1(7): 38 -46 .